SEC Form 4 reporting owner

Waheed Nadia

Waheed Nadia has filed 5 Form 4 transactions reported between January 2, 2026 and June 3, 2026, as Chief Medical Officer of OCULAR THERAPEUTIX, INC.

Name as filed: Waheed Nadia

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$221K
3 lines
Companies
1
with Form 4 filings
Latest transaction
Jun 3, 2026
transaction date

Roles and reported holdings

  • OCULOCULAR THERAPEUTIX, INC
    Jan 2, 2026 – Jun 3, 2026

    Chief Medical Officer

    Held directly300,079 sh as of Jun 3, 2026 · Form 4

    24 months: $221K sold

Transaction history

All 5 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 3, 2026OCULChief Medical OfficerOpen-market saleCode S · direct14,828$123K@ $8.27Form 4
Feb 20, 2026OCULChief Medical OfficerOpen-market saleCode S · direct3,510$27K@ $7.74Form 4
Feb 12, 2026OCULChief Medical OfficerOpen-market saleCode S · direct7,863$71K@ $9.04Form 4
Jan 2, 2026OCULChief Medical OfficerGrant or awardCode A · direct240,932—Form 4
Jan 2, 2026OCULChief Medical OfficerGrant or awardCode A · direct79,112—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.